LT4048278T - Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną - Google Patents

Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną

Info

Publication number
LT4048278T
LT4048278T LTEPPCT/US2020/056408T LTUS2020056408T LT4048278T LT 4048278 T LT4048278 T LT 4048278T LT US2020056408 T LTUS2020056408 T LT US2020056408T LT 4048278 T LT4048278 T LT 4048278T
Authority
LT
Lithuania
Prior art keywords
morpholinoazetidin
dioxopiperidin
isoindoline
benz
dione
Prior art date
Application number
LTEPPCT/US2020/056408T
Other languages
English (en)
Inventor
Maria Soraya ANTON
Tonia J. Buchholz
Shailaja Kasibhatla
Antonia Lopez-Girona
Rama Narla
Michael POURDEHNAD
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of LT4048278T publication Critical patent/LT4048278T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2020/056408T 2019-10-21 2020-10-20 Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną LT4048278T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962924028P 2019-10-21 2019-10-21
PCT/US2020/056408 WO2021080935A1 (en) 2019-10-21 2020-10-20 Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
LT4048278T true LT4048278T (lt) 2023-12-11

Family

ID=73449175

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/056408T LT4048278T (lt) 2019-10-21 2020-10-20 Hematologinio piktybinio naviko gydymo būdai, panaudojant 2-(2,6- dioksopiperidin-3-il)-4-((2-fluor-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)izoindolin-1,3-dioną

Country Status (21)

Country Link
US (2) US11666579B2 (lt)
EP (1) EP4048278B1 (lt)
JP (1) JP2022552882A (lt)
KR (1) KR20220103722A (lt)
CN (2) CN115919871A (lt)
AU (1) AU2020372330A1 (lt)
BR (1) BR112022007417A2 (lt)
CA (1) CA3154504A1 (lt)
DK (1) DK4048278T3 (lt)
ES (1) ES2967929T3 (lt)
FI (1) FI4048278T3 (lt)
HR (1) HRP20231487T1 (lt)
HU (1) HUE064768T2 (lt)
IL (1) IL292266A (lt)
LT (1) LT4048278T (lt)
MX (1) MX2022004683A (lt)
PL (1) PL4048278T3 (lt)
PT (1) PT4048278T (lt)
RS (1) RS64936B1 (lt)
SI (1) SI4048278T1 (lt)
WO (1) WO2021080935A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666579B2 (en) * 2019-10-21 2023-06-06 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102191256B1 (ko) * 2014-10-30 2020-12-15 강푸 바이오파마슈티칼즈 리미티드 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용
WO2019209692A1 (en) * 2018-04-23 2019-10-31 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
US11666579B2 (en) * 2019-10-21 2023-06-06 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Also Published As

Publication number Publication date
DK4048278T3 (da) 2024-01-08
HRP20231487T1 (hr) 2024-03-01
JP2022552882A (ja) 2022-12-20
KR20220103722A (ko) 2022-07-22
CN115087448A (zh) 2022-09-20
CN115919871A (zh) 2023-04-07
PT4048278T (pt) 2024-01-12
CA3154504A1 (en) 2021-04-29
EP4048278B1 (en) 2023-11-01
AU2020372330A1 (en) 2022-05-19
PL4048278T3 (pl) 2024-03-18
SI4048278T1 (sl) 2024-01-31
WO2021080935A1 (en) 2021-04-29
RS64936B1 (sr) 2024-01-31
MX2022004683A (es) 2022-05-10
US11666579B2 (en) 2023-06-06
HUE064768T2 (hu) 2024-04-28
EP4048278A1 (en) 2022-08-31
BR112022007417A2 (pt) 2022-07-12
FI4048278T3 (fi) 2023-12-19
US20210113577A1 (en) 2021-04-22
US20230277548A1 (en) 2023-09-07
ES2967929T3 (es) 2024-05-06
IL292266A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL287145A (en) Methods for treating non-Hondkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 , 3-dione
SG11202011568XA (en) Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
EP4048668A4 (en) METHODS OF TREATING HEMATOLOGICAL CANCER AND USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL) BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
SI3580208T1 (sl) Derivati 2-(3-(1H-benzo(d)imidazol-1-il)propil)piperidin-3-ol in sorodne spojine kot zaviralci PRS za zdravljenje na primer raka
RS64029B1 (sr) Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida
MY185516A (en) Compositions and methods for treating schizophrenia
MX2018007147A (es) Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion.
MX2019002697A (es) Composiciones para comprimidos.
IL292266A (en) Methods for the treatment of hematological malignancy using -(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1.3-dione)
IL284509A (en) Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide
IL284680A (en) Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same
IL292265A (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion
EP3873498A4 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE NUCLEIC ACIDS
IL284665A (en) Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same
IL307942A (en) Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione
IL292258A (en) Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them